Advances in the study of HLA-restricted epitope vaccines

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 12, 2013, Pages 2566-2577

  Zhao, Lingxiao ^a   Zhang, Min ^a   Cong, Hua ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Adjuvant; Bioinformatic; Epitope vaccine; HLA restriction; MHC

Indexed keywords

ALUMINUM HYDROXIDE; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; HLA ANTIGEN; HLA RESTRICTED EPITOPE VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INTERLEUKIN 2; LISTERIOLYSIN O; MALARIA VACCINE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA ANTIGEN 4; MONTANIDE ISA 51; MUCIN 1; PEPTIDE VACCINE; PICIBANIL; PROTEIN E7; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WART VIRUS VACCINE;

ADJUVANT THERAPY; ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; CUTANEOUS MELANOMA; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE FREE SURVIVAL; EPITOPE MAPPING; GENETIC LINKAGE; HELPER CELL; HUMAN; IMMUNOGENICITY; LUNG METASTASIS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; TUMOR REGRESSION;

ADJUVANT; BIOINFORMATIC; EPITOPE VACCINE; HLA RESTRICTION; MHC;

B-LYMPHOCYTES; BACTERIAL INFECTIONS; BIOMEDICAL RESEARCH; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HLA ANTIGENS; HUMANS; NEOPLASMS; PARASITIC DISEASES; VACCINES, SUBUNIT; VIRUS DISEASES;

EID: 84893112391     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26088     Document Type: Article

References (101)

1. Jenner E. An inquiry into the causes and effects of the Variolae Vaccinae a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the Cow Pox. London: Printed for the author by Sampson Low, 1798
2. O'Hagan D.T., MacKichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng 2001; 18: 69-85; PMID: 11566599; htt (Pubitemid 32889607)
3. Hämmerling G.J., Vogt AB, Kropshofer H. Antigen processing and presentation-towards the millennium. Immunol Rev 1999; 172: 5-9; PMID: 10631932; http://dx.doi.org/10.1111/j.1600-065X.1999.tb01351.x
4. Gras S, Burrows SR, Turner S.J., Sewell AK, McCluskey J, Rossjohn J. A structural voyage toward an understanding of the MHC-I-restricted immune response: lessons learned and much to be learned. Immunol Rev 2012; 250: 61-81; PMID: 23046123; http://dx.doi.org/10.1111/j.1600-065X.2012.01159.x
5. Zinkernagel RM, Doherty PC. Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 1974; 251: 547-8; PMID: 4547543; http://dx.doi.org/10.1038/251547a0
6. Akkina R. Human immune responses and potential for vaccine assessment in humanized mice. Curr Opin Immunol 2013; 25: 403-9; PMID: 23628166; http://dx.doi.org/10.1016/j.coi.2013.03.009
7. Sidney J, del Guercio MF, Southwood S, Engelhard VH, Appella E, Rammensee H.G., Falk K., Rötzschke O, Takiguchi M., Kubo RT, et al. Several HLA alleles share overlapping peptide specificities. J Immunol 1995; 154: 247-59; PMID: 7527812
8. Barber LD, Gillece-Castro B, Percival L., Li X, Clayberger C, Parham P. Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes. Curr Biol 1995; 5: 179-90; PMID: 7743181; http://dx.doi.org/10.1016/S0960-9822(95)00039-X
9. Walter S., Weinschenk T, Reinhardt C., Singh-Jasuja H. Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. Oncoimmunology 2013; 2: e22246; PMID: 23482454; http://dx.doi.org/10.4161/onci.22246
10. Walter S., Weinschenk T, Stenzl A., Zdrojowy R, Pluzanska A, Szczylik C., Staehler M, Brugger W, Dietrich P.Y., Mendrzyk R., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-61; PMID: 22842478; http://dx.doi.org/10.1038/nm.2883
11. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228: 1315-7; PMID: 4001944; http://dx.doi.org/10.1126/science.4001944 (Pubitemid 15000355)
12. Scott JK, Smith GP. Searching for peptide ligands with an epitope library. Science 1990; 249: 386-90; PMID: 1696028; http://dx.doi.org/10.1126/ science.1696028
13. Beghetto E, Spadoni A, Buffolano W., Del Pezzo M, Minenkova O, Pavoni E., Pucci A, Cortese R, Felici F., Gargano N. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int J Parasitol 2003; 33: 163-73; PMID: 12633654; http://dx.doi.org/10.1016/S0020-7519(02)00256-4 (Pubitemid 36298987)
14. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 2004; 4: 648-55; PMID: 15286731; http://dx.doi.org/10.1038/nri1416 (Pubitemid 39025050)
15. Chen DS, Soen Y, Stuge T.B., Lee PP, Weber JS, Brown PO, Davis MM. Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med 2005; 2: e265; PMID: 16162034; http://dx.doi.org/10.1371/journal.pmed.0020265 (Pubitemid 41554079)
16. Kern F, Surel IP, Brock C, Freistedt B., Radtke H, Scheffold A, Blasczyk R., Reinke P, Schneider-Mergener J, Radbruch A, et al. T-cell epitope mapping by flow cytometry. Nat Med 1998; 4: 975-8; PMID: 9701254; http://dx.doi.org/10. 1038/nm0898-975 (Pubitemid 28364041)
17. Czerkinsky C, Andersson G, Ekre H.P., Nilsson LÅ, Klareskog L, Ouchterlony Ö. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J Immunol Methods 1988; 110: 29-36; PMID: 3131436; http://dx.doi.org/10.1016/0022-1759(88) 90079-8
18. Li Pira G., Ivaldi F, Tripodi G., Martinengo M, Manca F. Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems: potential applications for adoptive cellular immunoreconstitution. J Immunother 2008; 31: 762-70; PMID: 18779743; http://dx.doi.org/10.1097/CJI.0b013e3181826232
19. Wallace PK, Tario JD Jr., Fisher J.L., Wallace SS, Ernstoff MS, Muirhead KA. Tracking antigen-driven responses by flow cytometry: monitoring proliferation by dye dilution. Cytometry a 2008; 73: 1019-34; PMID: 18785636; http://dx.doi.org/10.1002/cyto.a.20619
20. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open biology 2013; 3.
21. Rammensee H, Bachmann J, Emmerich N.P., Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-9; PMID: 10602881; http://dx.doi.org/10.1007/s002510050595 (Pubitemid 30099526)
22. Elfaki ME, Khalil EA, De Groot AS, Musa AM, Gutiérrez A, Younis B.M., Salih KA, El-Hassan AM. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother 2012; 8: 1769-74; PMID: 22922767; http://dx.doi.org/10.4161/hv.21881
23. Sturniolo T, Bono E, Ding J., Raddrizzani L, Tuereci O, Sahin U., Braxenthaler M, Gallazzi F, Protti M.P., Sinigaglia F., et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555-61; PMID: 10385319; http://dx.doi.org/10.1038/9858 (Pubitemid 29262918)
24. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152: 163-75; PMID: 8254189
25. Bisset LR, Fierz W. Using a neutral network to identify potential HLA-DR1 binding sites within proteins. Mol Recognit 1993; 6: 41-8; http://dx.doi.org/ 10.1002/jmr.300060105
26. Gulukota K, DeLisi C. Neural network method for predicting peptides that bind major histocompatibility complex molecules. Methods Mol Biol 2001; 156: 201-9; PMID: 11068761
27. Honeyman MC, Brusic V, Stone N.L., Harrison LC. Neural network-based prediction of candidate T-cell epitopes. Nat Biotechnol 1998; 16: 966-9; PMID: 9788355; http://dx.doi.org/10.1038/nbt1098-966 (Pubitemid 28483627)
28. Brusic V, Rudy G, Honeyman G., Hammer J, Harrison L. Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network. Bioinformatics 1998; 14: 121-30; PMID: 9545443; http://dx.doi.org/10. 1093/bioinformatics/14.2.121 (Pubitemid 28395870)
29. Delorenzi M, Speed T. An HMM model for coiled-coil domains and a comparison with PSSM-based predictions. Bioinformatics 2002; 18: 617-25; PMID: 12016059; http://dx.doi.org/10.1093/bioinformatics/18.4.617 (Pubitemid 34521050)
30. Dönnes P., Elofsson A. Prediction of MHC class I binding peptides, using SVMHC. BMC Bioinformatics 2002; 3: 25; PMID: 12225620; http://dx.doi.org/10.1186/1471-2105-3-25 (Pubitemid 38751179)
31. Zhao Y, Pinilla C, Valmori D., Martin R, Simon R. Application of support vector machines for T-cell epitopes prediction. Bioinformatics 2003; 19: 1978-84; PMID: 14555632; http://dx.doi.org/10.1093/bioinformatics/btg255 (Pubitemid 37322343)
32. Andersen MH, Tan L, Søndergaard I, Zeuthen J, Elliott T., Haurum JS. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 2000; 55: 519-31; PMID: 10902608; http://dx.doi.org/10.1034/j.1399-0039.2000.550603.x (Pubitemid 30386454)
33. Atanasova M, Dimitrov I, Flower D.R., Doytchinova I. MHC class II binding prediction by molecular docking. Molecular Informatics 2011; 30: 368-75; http://dx.doi.org/10.1002/minf.201000132
34. Bhasin M, Raghava GPS. Prediction of CTL epitopes using QM, SVM and ANN techniques. Vaccine 2004; 22: 3195-204; PMID: 15297074; http://dx.doi.org/10. 1016/j.vaccine.2004.02.005 (Pubitemid 39037225)
35. Izumoto S. Peptide vaccine. Glioma. Springer New York 2012; 166-77.
36. Brossart P, Heinrich KS, Stuhler G, Behnke L., Reichardt VL, Stevanovic S, Muhm A, Rammensee H.G., Kanz L., Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999; 93: 4309-17; PMID: 10361129 (Pubitemid 29279274)
37. Kohlgraf KG, Gawron AJ, Higashi M, Van Lith ML, Shen X, Caffrey TC, Anderson J.M., Hollingsworth MA. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 2004; 53: 1068-84; PMID: 15696607; http://dx.doi.org/10.1007/s00262-004-0557-1 (Pubitemid 39506396)
38. Jothy S, Brazinsky SA, Chin-A-Loy M, Haggarty A, Krantz M.J., Cheung M., Fuks A. Characterization of monoclonal antibodies to carcinoembryonic antigen with increased tumor specificity. Lab Invest 1986; 54: 108-17; PMID: 2417036 (Pubitemid 16163884)
39. Li D, Hua S, Fan Y., Xu S, Duan X, Liu L., Che Y, Li S, Tan Y. DNA vaccine expressing repeated carcinoembryonic antigen (CEA)(625-667) induces strong immunity in mice. Immunol Lett 2011; 135: 124-8; PMID: 21073899; http://dx.doi.org/10.1016/j.imlet.2010.10.012
40. Peoples GE, Goedegebuure PS, Smith R, Linehan D.C., Yoshino I., Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92: 432-6; PMID: 7831305; http://dx.doi.org/10.1073/pnas.92.2.432
41. Slamon DJ, Godolphin W, Jones L.A., Holt JA, Wong SG, Keith DE, Levin W.J., Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12; PMID: 2470152; http://dx.doi.org/10.1126/science.2470152 (Pubitemid 19147683)
42. Fisk B, Blevins TL, Wharton J.T., Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-17; PMID: 7539040; http://dx.doi.org/10.1084/jem.181.6.2109
43. z.ast;0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol 2011; 186: 685-96; PMID: 21149604; http://dx.doi.org/10.4049/jimmunol.1001775
44. Roeder C, Schuler-Thurner B, Berchtold S., Vieth G, Driesch Pv, Schuler G, Lüftl M. MAGE-A3 is a frequent tumor antigen of metastasized melanoma. Arch Dermatol Res 2005; 296: 314-9; PMID: 15570431; http://dx.doi.org/10.1007/ s00403-004-0527-7 (Pubitemid 40169524)
45. Tajima K, Obata Y, Tamaki H., Yoshida M, Chen YT, Scanlan M.J., Old LJ, Kuwano H, Takahashi T, Takahashi T., et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003; 42: 23-33; PMID: 14512184; http://dx.doi.org/10.1016/S0169-5002(03)00244-7 (Pubitemid 37153132)
46. Filho PA, López-Albaitero A, Xi L, Gooding W., Godfrey T, Ferris RL. Quantitative expression and immunogenicity of MAGE-3 and -6 in upper aerodigestive tract cancer. Int J Cancer 2009; 125: 1912-20; PMID: 19610063; http://dx.doi.org/10.1002/ijc.24590
47. Luo G, Huang S, Xie X., Stockert E, Chen YT, Kubuschok B, Pfreundschuh M. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2002; 2: 11; PMID: 12747756
48. Jungbluth AA, Ely S, DiLiberto M., Niesvizky R, Williamson B, Frosina D., Chen YT, Bhardwaj N, Chen-Kiang S, Old LJ, et al. The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 2005; 106: 167-74; PMID: 15761016; http://dx.doi.org/10.1182/blood-2004-12-4931 (Pubitemid 40967189)
49. Khammari A, Labarrière N, Vignard V., Nguyen JM, Pandolfino MC, Knol AC, Quéreux G, Saiagh S., Brocard A, Jotereau F, et al. Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol 2009; 129: 2835-42; PMID: 19554023; http://dx.doi.org/10.1038/jid.2009.144
50. Li Y, Liu S, Hernandez J., Vence L, Hwu P, Radvanyi L., Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010; 184: 452-65; PMID: 19949105; http://dx.doi.org/10.4049/jimmunol.0901101
51. z.ast;0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res 2011; 71: 1406-17; PMID: 21159666; http://dx.doi.org/10.1158/0008-5472.CAN-10-1296
52. Vasievich EA, Ramishetti S, Zhang Y., Huang L. Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model. Mol Pharm 2012; 9: 261-8; PMID: 22142394; http://dx.doi.org/10.1021/mp200350n
53. Schwartzentruber DJ, Lawson DH, Richards J.M., Conry RM, Miller DM, Treisman J, Gailani F., Riley L, Conlon K, Pockaj B., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011; 364: 2119-27; PMID: 21631324; http://dx.doi.org/10.1056/NEJMoa1012863
54. Hu X, Chakraborty NG, Sporn J.R., Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479-83; PMID: 8653680 (Pubitemid 26170677)
55. Takahashi N, Ohkuri T, Homma S., Ohtake J, Wakita D, Togashi Y., Kitamura H, Todo S, Nishimura T. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012; 103: 150-3; PMID: 22221328; http://dx.doi.org/10.1111/j.1349-7006.2011.02106.x
56. Arteaga CL, Sliwkowski MX, Osborne C.K., Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012; 9: 16-32; PMID: 22124364; http://dx.doi.org/10.1038/nrclinonc.2011.177
57. Holmes JP, Benavides LC, Gates J.D., Carmichael MG, Hueman MT, Mittendorf EA, Murray J.L., Amin A., Craig D, von Hofe E, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26: 3426-33; PMID: 18612158; http://dx.doi.org/10.1200/JCO.2007.15.7842
58. Positive Phase II interim data on AE37 cancer vaccine released. Hum Vaccin Immunother 2012; 8: 152; PMID: 22426363
59. Mittendorf EA, Clifton GT, Holmes J.P., Clive KS, Patil R, Benavides LC, Gates J.D., Sears AK, Stojadinovic A, Ponniah S, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2012; 118: 2594-602; PMID: 21989902; http://dx.doi.org/10.1002/ cncr.26574
60. Holmes JP, Gates JD, Benavides L.C., Hueman MT, Carmichael MG, Patil R, Craig D., Mittendorf EA, Stojadinovic A, Ponniah S, et al. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer 2008; 113: 1666-75; PMID: 18726994; http://dx.doi.org/10.1002/ cncr.23772
61. Carmichael MG, Benavides LC, Holmes J.P., Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer 2010; 116: 292-301; PMID: 19924797; http://dx.doi.org/10.1002/cncr.24756
62. Dutoit V, Herold-Mende C, Hilf N., Schoor O, Beckhove P, Bucher J., Dorsch K, Flohr S, Fritsche J., Lewandrowski P, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 2012; 135: 1042-54; PMID: 22418738; http://dx.doi.org/10. 1093/brain/aws042
63. Kloverpris H, Karlsson I, Bonde J., Thorn M, Vinner L, Pedersen A.E., Hentze JL, Andresen BS, Svane IM, Gerstoft J, et al. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009; 23: 1329-40; PMID: 19528789; http://dx.doi.org/10.1097/QAD.0b013e32832d9b00
64. Jin X, Newman MJ, De-Rosa S, Cooper C., Thomas E, Keefer M, Fuchs J., Blattner W, Livingston BD, McKinney D.M., et al.; NIAID HIV Vaccine Trials Network. A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults. Vaccine 2009; 27: 7080-6; PMID: 19786145; http://dx.doi.org/10.1016/j.vaccine. 2009.09.060
65. Tan PT, Heiny AT, Miotto O, Salmon J., Marques ETA Jr., Lemonnier F., August JT. Conservation and diversity of influenza a H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One 2010; 5: e8754; PMID: 20090904; http://dx.doi.org/10.1371/journal.pone.0008754
66. z.ast;2402 human immunity model. PLoS One 2011; 6: e24626; PMID: 21949735; http://dx.doi.org/10.1371/journal.pone.0024626
67. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 (Suppl): E25-30; PMID: 10921378; http://dx.doi.org/10.1046/j.1440-1746.2000.02097.x (Pubitemid 30435732)
68. Ho GY, Burk RD, Klein S, Kadish A.S., Chang CJ, Palan P, Basu J, Tachezy R., Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995; 87: 1365-71; PMID: 7658497; http://dx.doi.org/10.1093/jnci/87.18.1365
69. Ding FX, Wang F, Lu Y.M., Li K., Wang KH, He XW, Sun SH. Multiepitope peptide-loaded viruslike particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009; 49: 1492-502; PMID: 19206147; http://dx.doi.org/10.1002/hep.22816
70. Muderspach L, Wilczynski S, Roman L., Bade L, Felix J, Small L.A., Kast WM, Fascio G, Marty V, Weber J. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000; 6: 3406-16; PMID: 10999722
71. de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, et al. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. Cancer Immunol Immunother 2012; 61: 1485-92; PMID: 22684521; http://dx.doi.org/10.1007/s00262-012-1292-7
72. Zhao C, Sun Y, Zhao Y., Wang S, Yu T, Du F., Yang XF, Luo E. Immunogenicity of a multi-epitope DNA vaccine against hantavirus. Hum Vaccin Immunother 2012; 8: 208-15; PMID: 22426376; http://dx.doi.org/10.4161/hv.18389
73. Maman Y, Nir-Paz R, Louzoun Y. Bacteria modulate the CD8+ T cell epitope repertoire of host cytosol-exposed proteins to manipulate the host immune response. PLoS Comput Biol 2011; 7: e1002220; PMID: 22022257; http://dx.doi.org/10.1371/journal.pcbi.1002220
74. Kono M, Nakamura Y, Suda T., Uchijima M, Tsujimura K, Nagata T., Giermasz AS, Kalinski P, Nakamura H, Chida K. Enhancement of protective immunity against intracellular bacteria using type-1 polarized dendritic cell (DC) vaccine. Vac cine 2012; 30: 2633-9; PMID: 22365841; http://dx.doi.org/10.1016/j.vaccine.2012. 02.026
75. z.ast;0201. Vaccine 2011; 29: 754-62; PMID: 21095258; http://dx.doi.org/10.1016/j.vaccine.2010.11. 015
76. z.ast;1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii. Immunome Res 2010; 6: 12; PMID: 21129215; http://dx.doi.org/10.1186/1745-7580-6-12
77. z.ast;0201-restricted cytotoxic T-cell epitopes of Trypanosoma cruzi TcP2β protein in HLA-transgenic mice and patients. Microbes Infect 2003; 5: 351-9; PMID: 12737989; http://dx.doi.org/10.1016/S1286-4579(03)00044-3 (Pubitemid 36553094)
78. Mahajan B, Berzofsky JA, Boykins R.A., Majam V., Zheng H, Chattopadhyay R, de la Vega P, Moch JK, Haynes J.D., Belyakov IM, et al. Multiple antigen peptide vaccines against Plasmodium falciparum malaria. Infect Immun 2010; 78: 4613-24; PMID: 20823210; http://dx.doi.org/10.1128/IaI.00533-10
79. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994; 12: 259-93; PMID: 8011283; http://dx.doi.org/10.1146/ annurev.iy.12.040194.001355 (Pubitemid 24140416)
80. Smith-Garvin J.E., Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol 2009; 27: 591-619; PMID: 19132916; http://dx.doi.org/10.1146/annurev. immunol.021908.132706
81. Grover HS, Blanchard N, Gonzalez F., Chan S, Robey EA, Shastri N. The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden. Infect Immun 2012; 80: 3279-88; PMID: 22778097; http://dx.doi.org/10. 1128/IAI.00425-12
82. z.ast;0702 mice. Hum Immunol 2012; 73: 1-10; PMID: 22027386; http://dx.doi.org/10.1016/j. humimm.2011.10.006
83. Oseroff C, Sette A, Wentworth P, Celis E, Maewal A., Dahlberg C, Fikes J, Kubo R.T., Chesnut RW, Grey HM, et al. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vac cine 1998; 16: 823-33; PMID: 9627940; http://dx.doi.org/10.1016/S0264-410X(97)00264-8 (Pubitemid 28236652)
84. Hughes HR, Crill WD, Davis B.S., Chang GJ. A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines. Virology 2012; 424: 129-37; PMID: 22244913; http://dx.doi.org/10.1016/j.virol. 2011.12.012
85. Zhou B, Liu K, Jiang Y., Wei JC, Chen PY. Multiple linear B-cell epitopes of classical swine fever virus glycoprotein E2 expressed in E.coli as multiple epitope vaccine induces a protective immune response. Virol J 2011; 8: 378; PMID: 21801433; http://dx.doi.org/10.1186/1743-422X-8-378
86. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112: 1570-80; PMID: 18725575; http://dx.doi.org/10.1182/blood-2008-02- 078071
87. Wang F, Feng X, Zheng Q., Hou H, Cao R, Zhou B., Liu Q, Liu X, Pang R., Zhao J, et al. Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response. Virol J 2012; 9: 204; PMID: 22985466; http://dx.doi.org/10.1186/1743- 422X-9-204
88. Bins AD, van den Berg JH, Oosterhuis K, Haanen JB. Recent advances towards the clinical application of DNA vaccines. Neth J Med 2013; 71: 109-17; PMID: 23712805
89. Oosterhuis K, Aleyd E, Vrijland K, Schumacher TN, Haanen JB. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Hum Gene Ther 2012; 23: 1301-12; PMID: 22971245; http://dx.doi.org/10.1089/hum.2012.101
90. Kang TH, Kim KW, Bae H.C., Seong SY, Kim TW. Enhancement of DNA vaccine potency by antigen linkage to IFN-γ-inducible protein-10. Int J Cancer 2011; 128: 702-14; PMID: 20473881; http://dx.doi.org/10.1002/ijc.25391
91. Dong JC, Kobinger GP. Hypothesis driven development of new adjuvants: Short peptides as immunomodulators. Hum Vaccin Immunother 2013; 9; PMID: 23563510; http://dx.doi.org/10.4161/hv.22972
92. Golkar M, Shokrgozar MA, Rafati S, Musset K., Assmar M, Sadaie R, Cesbron-Delauw MF, Mercier C. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid a (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 2007; 25: 4301-11; PMID: 17418457; http://dx.doi.org/10.1016/j.vaccine.2007.02.057 (Pubitemid 46646961)
93. Schijns VE. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12: 456-63; PMID: 10899018; http://dx.doi.org/10.1016/S0952- 7915(00)00120-5 (Pubitemid 30410353)
94. Scheifele DW, Dionne M, Ward B.J., Cooper C., Vanderkooi OG, Li Y, Halperin SA; PHAC/CIHR Influenza Research Network. Safety and immunogenicity of 2010-2011 A/H1N1pdm09-containing trivalent inactivated influenza vaccine in adults previously given AS03-adjuvanted H1N1 2009 pandemic vaccine: results of a randomized trial. Hum Vaccin Immunother 2013; 9: 136-43; PMID: 23570051; http://dx.doi.org/10.4161/hv.22619
95. Reed SG, Bertholet S, Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009; 30: 23-32; PMID: 19059004; http://dx.doi.org/10.1016/j.it.2008.09.006
96. Zonneveld-Huijssoon E., van Wijk F, Roord S, Delemarre E., Meerding J, de Jager W, Klein M, Raz E., Albani S, Kuis W, et al. TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis. Ann Rheum Dis 2012; 71: 1706-15; PMID: 22562976; http://dx.doi.org/ 10.1136/annrheumdis-2011-201131
97. Hamdy S, Haddadi A, Hung R.W., Lavasanifar A. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63: 943-55; PMID: 21679733; http://dx.doi.org/10.1016/j.addr.2011.05.021
98. Partidos CD, Vohra P, Anagnostopoulou C., Jones DH, Farrar GH, Steward M W. Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol Immunol 1996; 33: 485-91; PMID: 8700164; http://dx.doi.org/10.1016/0161-5890(96)00032-6 (Pubitemid 26228385)
99. Bae J, Smith R, Daley J., Mimura N, Tai YT, Anderson K.C., Munshi NC. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: A potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res 2012; 18: 4850-60; PMID: 22753586; http://dx.doi.org/10.1158/1078-0432.CCR-11-2776
100. Suzuki H, Fukuhara M, Yamaura T., Mutoh S, Okabe N, Yaginuma H., Hasegawa T, Yonechi A, Osugi J., Hoshino M, et al. Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 2013; 11: 97; PMID: 23578144; http://dx.doi.org/10.1186/1479-5876-11-97
101. Cong H, Gu QM, Yin H.E., Wang JW, Zhao QL, Zhou HY, Li Y, Zhang JQ. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii. Vaccine 2008; 26: 3913-21; PMID: 18555564; http://dx.doi.org/10.1016/j.vaccine.2008.04.046